How EMA Supports Innovation by Small and Medium-Sized Enterprises
The development of innovative medicines and technologies has been shown to be key to tackling serious unmet medical need. Many such innovations stem from micro, small, and medium-sized enterprises (SMEs), from academia and from not-for-profit organizations. In fact, across all industries SMEs have been found to be the main fabric of Europe’s economy.
However, cost is often a barrier for these research organizations, including the cost of filing regulatory submissions. To support innovation and help SMEs bring products to the market, the European Medicines Agency offers significant benefits, including fee exemptions and reductions for regulatory submissions and for scientific advice. (See Fee Incentives chart)
